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A B S T R A C T
Objectives: Recommendations in clinical practice guidelines (CPG) may differ and cause confusion. Our
objective was to appraise CPGs for antifungal treatment of invasive candidiasis (IC) in non-neutropenic
critically ill adult patients.
Methods: We systematically searched the literature for CPGs published between 2008 and 2018. We
assessed the quality of each guideline using six domains of the AGREE II instrument. We extracted and
compared recommendations for different treatment strategies and assessed content quality.
Results: Of 19 guidelines, the mean overall AGREE II score was 58%. The domain ‘clarity of presentation’
received the highest scores (88%) and ‘applicability’ the lowest (18%). CPGs provided detailed
recommendations on antifungal prophylaxis (n = 10), with fluconazole recommended as initial
prophylaxis in all seven CPGs citing a specific drug. Echinocandin was recommended as the initial
drug in all 16 CPGs supporting empirical/pre-emptive treatment; and in 18 of 19 for targeted invasive
candidiasis treatment. However, it remains unclear when to initiate prophylaxis, empirical or pre-
emptive therapy or when to step down.
Conclusions: The methodological quality of CPGs for antifungal treatment of IC in non-neutropenic
critically ill patients is suboptimal. Some treatment recommendations were inconsistent across
indications and require local guidance to help clinicians make better informed decisions.
© 2019 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Invasive candidiasis (IC) is one of the most common health care-
associated infections contracted by patients in intensive care units
(ICUs), and is widely recognized as a major cause of mortality,
morbidity and considerable health expenditure (Calandra et al.,
2016, Dodds Ashley et al., 2012, Kollef et al., 2012, Lortholary et al.,
2014, Vincent et al., 2009, Wisplinghoff et al., 2004). The increased* Corresponding author at: School of Pharmacy, The University of Queensland,
Woolloongabba, Queensland, Australia
E-mail addresses: wangyan0819@mail.xjtu.edu.cn (Y. Wang),
t.mcguire@uq.edu.au, treasure.mcguire@mater.org.au, tmcguire@bond.edu.au
(T.M. McGuire), s.hollingworth@uq.edu.au (S.A. Hollingworth),
dongyalin@mail.xjtu.edu.cn (Y. Dong), m.vandriel@uq.edu.au (M.L. Van Driel).
https://doi.org/10.1016/j.ijid.2019.10.016
1201-9712/© 2019 The Author(s). Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).use of newer antifungal agents with improved tolerability is due to
wider availability and use by non-expert practitioners in both the
prevention and treatment of IC, leading to drug resistance and
wasted resources (Arendrup and Patterson, 2017).
Clinical practice guidelines (CPGs) aim to bridge the gap
between research and practice (Bero et al., 1998). Clinicians rely on
guideline recommendations to inform practice and assume they
are consistent and based on evidence. Recommendations in CPGs
are often used to assess the appropriateness of adherence to
antifungal prescribing (Nivoix et al., 2012, Valerio et al., 2014) but
the information in CPGs is sometimes conflicting and confusing.
The reasons for the difference in recommendations among CPGs
could include insufficient evidence, different interpretation of the
evidence, or non-systematic methods for guideline development
(Burgers et al., 2002, Eisinger et al., 1999, Fahey and Peters, 1996).
CPGs for antifungal treatment differ in their aims and objectives,ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
138 Y. Wang et al. / International Journal of Infectious Diseases 89 (2019) 137–145methods, rigor of development, and overall recommendations
(Agrawal et al., 2012, Deshpande et al., 2013, Leroux and Ullmann,
2013). These inconsistences in guidelines can limit clinicians’
appropriate treatment decisions.
CPG recommendations for antifungal treatment may differ
within particular patient groups, for example pediatric (Morgan
et al., 2017) and adult hematology/oncology (Agrawal et al., 2012)
patients. Studies reporting on the transparency of the guideline
process for antifungal treatment of IC in non-neutropenic critically
ill adult patients and how this relates to recommendations are
lacking. We aimed to analyze and compare the recommendations
in CPGs for antifungal treatment of IC in non-neutropenic critically
ill adult patients. In order to review the guideline development
process, we aimed to evaluate the quality of CPGs using a
systematic critical appraisal approach (Appraisal of Guidelines for
Research and Evaluation [AGREE II] instrument).
Materials and methods
Searches
A librarian guided a systematic search of four databases
(PubMed, Cochrane, Embase, CINAHL, and China National Knowl-
edge Infrastructure [CNKI]) to identify articles published between
1 January 2008 and 30 December 2018, using the terms of fungal
disease (fung* OR mycoses OR antifung* OR Candida* OR yeast*)
and classified as “clinical guidelines” using ‘Practice Guidelines as
Topic’ as MeSH terms and ‘guideline*’ as text word. We also
searched four guideline repositories: Guidelines International
Network (GIN) (http://www.g-i-n.net/), the National Institute for
Health and Care Excellence (NICE) (http://www.nice.org.uk/),
National Health and Medical Research Council (NHMRC) (http://
www.nhmrc.gov.au/), and the National Guideline Clearinghouse
(NGC) (http://www.guideline.gov/). References of retrieved
articles were searched manually for further references to guide-
lines. No language restriction was applied.Figure 1. PRISMA flow diagram of clinInclusion criteria
The following inclusion criteria were applied:
1) Published guideline by a reputable health organization, society
or college of health professionals, or in a national or
international guideline repository;
2) Use of any antifungal agents in the setting of either prophylaxis,
empiric, pre-emptive, or targeted therapy for invasive Candida
infections (Guery et al., 2009);
3) Adult patients (defined by each guideline);
4) Explicit treatment recommendations for non-neutropenic
patients.
CPGs were excluded if:
1) the study population only involved children;
2) they were solely in the hemato-oncology or solid organ-
transplantation setting;
3) they only focused on other fungal infections, e.g., aspergillosis,
mucormycosis or trichosporonosis.
Study selection and data extraction
Two authors (YW and TM) independently screened the
titles, abstracts, and full texts of eligible articles. The final
inclusion of articles was agreed by consensus with a third
author (MVD).
The following data were extracted: country of origin, year of
publication, guideline developer, type of infection, and type of
antifungal treatment described. If the Grading of Recommen-
dations Assessment, Development and Evaluation (GRADE)
system was adopted in the guideline, this was noted (Guyatt
et al., 2008).ical practice guidelines selection.
Table 1
Characteristics of the included CPGs.
Guideline title Year Geographic
region
Name of organization Type of treatment covered Type of infection
IDSA guidelines Pappas
et al. (2016)
2016 USA Infectious Diseases Society of America Prophylaxis
Empirical or pre-emptive
therapy
Targeted therapy
Systematic
candidiasis
MEDICAL: Consensus
proposal Scudeller et al.
(2016)
2016 Italy Italian Society for Anti-Infective Therapy (SITA)
Italian Federation of Associations of Hospital
Doctors on Internal Medicine (FADOI)
Empirical or pre-emptive
therapy
Targeted therapy
Systematic
candidiasis
2016 IFI Taiwan guidelines
Kung et al. (2018)
2016 Taiwan Infectious Diseases Society of Taiwan Empirical or pre-emptive
therapy
Targeted therapy
Systematic
candidiasis
French IAI guidelines
Montravers et al. (2015)
2015 France French Society of Anesthesia and Reanimation Empirical or pre-emptive
therapy
Targeted therapy
Intra-abdominal
candidiasis
Middle East guidelines
Alothman et al. (2014)
2014 Middle East King Saud Bin Abdulaziz University for Health
Sciences
Empirical or pre-emptive
therapy
Targeted therapy
Systematic
candidiasis
Australian guidelines Chen
et al. (2014)
2014 Australia Royal Australasian College of Physicians Empirical or pre-emptive
therapy
Targeted therapy
Systematic
candidiasis
Iranian IC guidelines
Elhoufi et al. (2014)
2014 Iran IFI clinical forum comprising an Iranian panel of
intensive care experts
Prophylaxis
Empirical or pre-emptive
therapy
Targeted therapy
Systematic
candidiasis
JMF guidelines Kohno et al.
(2016)
2014 Japan Japanese Mycoses Forum Prophylaxis
Empirical or pre-emptive
therapy
Targeted therapy
Systematic
candidiasis
EPICO 2.0 project Zaragoza
et al. (2014)
2014 Spain Spanish Association of Mycology (AEM)
Spanish Society of Infectious Diseases and
Clinical Microbiology (SEIMC)
Spanish Society of Anesthesiology, Reanimation
and Pain Therapeutics (SEDAR)
Spanish Society of Critical, Intensive and
Coronary Medicine Units (SEMICYUC)
Spanish Society of Chemotherapy (SEQ)
Empirical or pre-emptive
therapy
Targeted therapy
Intra-abdominal
candidiasis
Chinese burn IFI guidelines
Luo et al. (2014)
2013 China Chinese Society of Burn Surgeons Prophylaxis
Empirical or pre-emptive
therapy
Targeted therapy
Burn invasive
fungal infection
Italian IAI guidelines
Bassetti et al. (2013)
2013 Italy Italian Society of Intensive Care
International Society of Chemotherapy
Prophylaxis
Empirical or pre-emptive
therapy
Targeted therapy
Intra-abdominal
candidiasis
ITALIC Scudeller et al.
(2014)
2013 Italy The Italian Society of Antimicrobial Therapy Prophylaxis
Empirical or pre-emptive
therapy
Targeted therapy
Systematic
candidiasis
JSMM Guidelines JSMM
(2013)
2013 Japan The Japanese Society for Medical Mycology Empirical or pre-emptive
therapy
Targeted therapy
Systematic
candidiasis
ESCMID guidelines Cornely
et al. (2012)
2012 Europe European Society for Clinical Microbiology and
Infectious Diseases
Prophylaxis
Empirical or pre-emptive
therapy
Targeted therapy
Systematic
candidiasis
Brazilian guidelines
Colombo et al. (2013)
2012 Brazil Sociedade Brasileira de Infectologia
Sociedade Paulista de Infectologia
Sociedade Brasileira de Medicina Tropical
Prophylaxis
Empirical or pre-emptive
therapy
Targeted therapy
Systematic
candidiasis
ATS guidelines Limper et al.
(2011)
2011 USA The American Thoracic Society Targeted therapy Systematic
candidiasis
German guidelines Ruhnke
et al. (2011)
2011 Germany German Speaking Mycological Society and the
Paul-Ehrlich-Society for Chemotherapy
Empirical or pre-emptive
therapy
Targeted therapy
Systematic
candidiasis
Spanish guideline for IC
Aguado et al. (2011)
2011 Spain Spanish Society of Infectious Diseases and
Clinical Microbiology (SEIMC)
Prophylaxis
Targeted therapy
Systematic
candidiasis
Canadian guidelines Bow
et al. (2010)
2010 Canada The Association of Medical Microbiology and
Infectious Disease Canada
Prophylaxis
Empirical or pre-emptive
therapy
Targeted therapy
Systematic
candidiasis
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We used the AGREE II tool (http://www.agreetrust.org/) to
assess the quality of the CPGs’ development process. It consists of
23 items grouped within six domains (scope and purpose,
stakeholder involvement, rigor of development, clarity of presen-
tation, applicability, and editorial independence) (Brouwers et al.,
2010a). In AGREE II, each item is scored using a seven-point Likert
scale where 1 represents a poor score and 7 represents excellent
demonstration of key quality criteria. Two authors (YW and MVD)
independently extracted data related to the AGREE tool and
discrepancies were resolved through discussion (YW, MVD, TM).
The final item scores were combined to provide a scaled domain
score (in percent). Inter-rater agreement was determined using
intraclass correlation coefficients (ICC) with a two-way random
effects model (Bartko, 1966). We calculated ICCs with 95%
confidence intervals for each domain and overall rating scores.
We classified level of reliability as poor (ICC < 0.40), moderate (ICC
0.40–0.59), substantial (ICC 0.60–0.79) or excellent level of
agreement (ICC 0.80–1.00). The Mann–Whitney U test (P < 0.05)
was used to compare the AGREE II scores of all guidelines by
separating the median publication time point of included guide-
lines (i.e. differences in domain scores between the newer and pre-
2014 CPGs). Statistical analyses were performed using SPSS version
19.0 (IBM SPSS Statistics, Xi’an, China).
Assessment: CPG recommendations
Each guideline was summarized by one author (YW) to identify
key points and recommendations. These summaries were checked
by a second author (MVD) for completeness and accuracy. The
primary characteristics and details of recommendations were
examined. CPG recommendations were tabulated and compared
by one author (YW) and then checked by other authors to ensure
they were correct for three clinical strategies: (1) antifungal
prophylaxis; (2) empirical or pre-emptive treatment; and (3)
targeted treatment.Table 2
CPGs AGREE II domain scores and quality assessment (%, ranked by overall assessment
Guideline title 1. Scope and
purpose
2. Stakeholder
involvement
3. Rigor of
development
ESCMID guidelines-2012 92 83 74 
IDSA guidelines-2016 75 33 86 
Canadian guidelines-2010 83 69 48 
Italian IAI guidelines-2013a 100 50 60 
ATS guidelines-2011 89 8 51 
German guidelines-2011 81 19 45 
French IAI guidelines-2015a 100 47 52 
Middle East guidelines-2014 75 44 46 
Iranian IC guidelines-2014 89 31 50 
Brazilian guidelines-2012 58 3 29 
2016 IFI Taiwan guidelines-
2016
75 33 68 
Australian guidelines-2014 97 8 49 
JMF guidelines-2014 89 33 29 
JSMM Guidelines-2013 89 28 44 
ITALIC-2013 89 33 39 
MEDICAL: Consensus
proposal-2016
100 31 24 
Spanish guideline for IC-
2011
86 36 35 
EPICO 2.0 project-2014a 100 28 47 
Chinese burn IFI guidelines-
2013
89 22 14 
Mean (SD) 87 (11) 34 (20) 47 (17) 
Median (Range) 89 (58–100) 33 (3–83) 47 (14–86) 
CPGs, clinical practice guidelines; AGREE, Appraisal of Guidelines for Research and Eva
a Guidelines for intra-abdominal candidiasis.Five key areas were selected to compare the content of the
recommendations and to highlight similarities and differences for
each of these strategies: the reason for initiating treatment; the
first choice of antifungal agents; the alternative choice of
antifungal agents; information on dosage, frequency; and
information on duration.
Results
Characteristics of selected guidelines
We identified 7230 relevant titles and selected 19 CPGs for
inclusion (Figure 1) (Aguado et al., 2011, Alothman et al., 2014,
Bassetti et al., 2013, Bow et al., 2010, Chen et al., 2014, Colombo
et al., 2013, Cornely et al., 2012, Elhoufi et al., 2014, JSMM, 2013,
Kohno et al., 2016, Kung et al., 2018, Limper et al., 2011, Luo et al.,
2014, Montravers et al., 2015, Pappas et al., 2016, Ruhnke et al.,
2011, Scudeller et al., 2016, Scudeller et al., 2014, Zaragoza et al.,
2014). Table 1 presents the main characteristics of included CPGs.
Most came from Europe (n = 8) and Asia (n = 5) and most were
developed by medical societies (n = 16). Eighteen of the 19 CPGs
provided recommendations for systematic (n = 15) and intra-
abdominal candidiasis (IAC) (n = 3). Of these 18 CPGs, all provided
specific details on targeted therapy,16 on empirical or pre-emptive
therapy and nine on prophylaxis. The single CPG on invasive fungal
infection (IFI) in burn patients gave guidance on all three
management strategies (targeted, empiric, and prophylaxis). Most
(n = 14) CPGs used the GRADE system for grading evidence (Aguado
et al., 2011, Alothman et al., 2014, Bassetti et al., 2013, Bow et al.,
2010, Colombo et al., 2013, Cornely et al., 2012, JSMM, 2013, Kohno
et al., 2016, Kung et al., 2018, Limper et al., 2011, Montravers et al.,
2015, Pappas et al., 2016, Ruhnke et al., 2011, Scudeller et al., 2014).
Assessment: methodological quality of CPG development
The standardized scores of each CPG by AGREE II domain and
the overall assessment are summarized in Table 2. The mean scoring).
4. Clarity of
presentation
5.
Applicability
6. Editorial
independence
Overall
assessment
100 46 88 100
97 44 50 92
100 2 92 92
81 10 38 83
100 2 42 83
100 6 0 75
69 15 0 67
81 23 50 58
92 38 8 58
89 17 38 58
75 33 46 50
89 8 38 50
100 19 25 50
94 3 0 50
86 23 67 42
86 38 92 33
97 2 50 33
53 2 17 25
72 2 42 17
88 (13) 18 (16) 41 (29) 59 (24)
89 (53–100) 15 (2–46) 42 (0–92) 58 (17–100)
luation.
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highest domain score was for ‘clarity of presentation’ (domain 4;
mean 88%, SD 13%), followed by ‘scope and purpose’ (domain 1;
mean 87%, SD 11%), while the other four domain scores were less
than 50%. ‘Applicability’ scored the lowest (domain 5; mean 18%,
SD 16%). The next lowest score was for ‘stakeholder involvement’
(domain 2; mean 34%, SD 20%). Differences in domain scores
between the newer and pre-2014 CPGs were not detected (see
Table S1).
Of the 19 CPGs, five had an overall assessment score of 80%
(Table 2). These included four CPGs for systematic candidiasis (Bow
et al., 2010, Cornely et al., 2012, Limper et al., 2011, Pappas et al.,
2016) and one for intra-abdominal candidiasis (Bassetti et al.,
2013). Only the CPG from ESCMID had scores greater than 70% in all
domains other than ‘applicability’ (domain 5) (Cornely et al., 2012).
Likewise, the applicability score for ESCMID was highest of all
CPGs. All five CPGs were either from North America (USA n = 2,
Canada n = 1) or Europe (n = 2). All the CPGs (except the American
Thoracic Society (ATS) guidelines (Limper et al., 2011)) provided
recommendations for all three treatment strategies (i.e. prophy-
laxis, empirical or pre-emptive, and targeted treatment).The inter-
rater reliability was classified as excellent for all domains and
substantial for overall assessment score (see Table S1).
Assessment: CPG recommendations
Prophylaxis
Half (n = 9) of the 18 candidiasis CPGs and one burn IFI CPG
provided recommendations about prophylaxis, with eight CPGs
including specific details for primary prophylaxis recipients
(Table 3). Three CPGs recommended antifungal prophylaxis for
patients who recently had abdominal surgery and recurrent
gastrointestinal perforations or anastomotic leakages (BassettiTable 3
Summary of recommendations for prophylaxis (n = 10) and empirical or pre-emptive t
Guideline title Initiation
mentioned
Initial drugs mentioned 
ECH FLU L-AMB 
Prophylaxis
IDSA guidelines-2016 U U 
Iranian IC guidelines-2014 U
JMF guidelines-2014 U 
Chinese burn IFI guidelines-2013 U U 
Italian IAI guidelines-2013a U U
ITALIC-2013 U 
ESCMID guidelines-2012 U U
Brazilian guidelines-2012 U
Spanish guideline for IC-2011 U 
Canadian guidelines-2010 U U 
Empirical or pre-emptive treatment
IDSA guidelines-2016 U 
MEDICAL: Consensus proposal-2016 U 
2016 IFI Taiwan guidelines-2016 U U U 
French IAI guidelines-2015a U U U
Middle East guidelines-2014 U 
Australian guidelines-2014 U 
Iranian IC guidelines-2014 U U 
JMF guidelines-2014 U U U 
EPICO 2.0 project-2014a U U 
Chinese burn IFI guidelines-2013 U U 
Italian IAI guidelines-2013a U U U 
ITALIC-2013 U U 
JSMM Guidelines-2013 U U U 
ESCMID guidelines-2012 U
Brazilian guidelines-2012 U 
German guidelines-2011 U U 
Canadian guidelines-2010 U U U 
ECH, Echinocandin; FLU, Fluconazole; L-AMB, Liposomal amphotericin B; D-AMB, Amp
a Guidelines for intra-abdominal candidiasis.et al., 2013, Bow et al., 2010, Cornely et al., 2012). Three guidelines
recommended prophylaxis for high-risk patients in ICU with a high
rate (>5% (Pappas et al., 2016) or >10% (Bow et al., 2010, Colombo
et al., 2013) of IC. Antifungal prophylaxis was generally not
recommended by the other two CPGs in non-neutropenic critically
ill patients (Kohno et al., 2016, Scudeller et al., 2014). The guideline
for burn patients outlined special conditions required for
commencing antifungal prophylaxis (e.g. moderate to severe
inhalation injury is present) (Luo et al., 2014).
A specific drug was mentioned in seven of the ten guidelines
that described prophylaxis: fluconazole was recommended as the
initial drug of choice in all seven CPGs (Aguado et al., 2011, Bassetti
et al., 2013, Bow et al., 2010, Cornely et al., 2012, Elhoufi et al., 2014,
Luo et al., 2014, Pappas et al., 2016). Echinocandin was mentioned
as an acceptable alternative in only two CPGs (Bassetti et al., 2013,
Pappas et al., 2016).
Only the Canadian CPG mentioned the duration of prophylaxis;
until either complete resolution of intra-abdominal disease on
development of proven Candida species infection requiring
directed antifungal therapy, or development of a severe drug-
related adverse event (Bow et al., 2010).
Empirical or pre-emptive treatment
Recommendations for empirical or pre-emptive treatment
were mentioned in 16 of the 18 candidiasis CPGs (89%) and the
single Chinese burn IFI CPG (Luo et al., 2014) (Table 3). Ten
guidelines recommended the initiation of empirical or pre-
emptive treatment (six IC CPGs, all three IAC CPGs, and the burn
IFI CPG). The ESCMID guidelines stated that the optimal time point
for initiating empirical antifungal treatment remains unclear in
fever patients (Cornely et al., 2012), whereas the JSMM guidelines
recommended that patients with unknown fever with ineffective
antimicrobial therapy for four days should be given empiricalreatment (n = 17).
Alternative drugs mentioned Dosage
mentioned
Duration
mentioned
FLU L-AMB VOR D-AMB ECH
U U
U
U
U
U U
U
U U U U
U
U
U U U U U
U U U
U U
U
U
U U
U U U
U U U
U U U
U U U
U
U U
hotericin B deoxycholate; VOR, Voriconazole; ITR, itraconazole.
142 Y. Wang et al. / International Journal of Infectious Diseases 89 (2019) 137–145antifungal treatment (JSMM, 2013). Three CPGS advised testing for
(1,3)-β-D-glucan in serum or plasma as a prompt for antifungal
treatment (Cornely et al., 2012, Kohno et al., 2016, Scudeller et al.,
2014). In terms of Candida colonization, the ESCMID and Canadian
CPGs concluded that antifungal treatment is not recommended in
non-neutropenic patients in the presence of colonization (isolation
from respiratory secretions) (Bow et al., 2010, Cornely et al., 2012).
However, two CPGs regarded Candida colonization at more than
one site as a reason for initiation (Kohno et al., 2016, Kung et al.,
2018). One CPG for IAC recommended all critically ill patients
receive antifungal treatment (Bassetti et al., 2013). Two CPGs for
IAC recommended antifungal treatment for patients with either
secondary nosocomial peritonitis and with risk factors for Candida
spp. colonization or patients with tertiary peritonitis (Montravers
et al., 2015, Zaragoza et al., 2014). One IFI CPG noted the particular
conditions required for initiating antifungal empirical treatment in
burn patients (e.g. burn patients who have received two different
broad spectrum antibiotics for a minimum of five days) (Luo et al.,
2014).
With the exception of the ESCMID guideline (Cornely et al.,
2012), echinocandins were recommended as the initial drug in
all 16 CPGs that supported empirical or pre-emptive treatment
(Alothman et al., 2014, Bassetti et al., 2013, Bow et al., 2010,
Chen et al., 2014, Colombo et al., 2013, Elhoufi et al., 2014, JSMM,
2013, Kohno et al., 2016, Kung et al., 2018, Luo et al., 2014,
Montravers et al., 2015, Pappas et al., 2016, Ruhnke et al., 2011,
Scudeller et al., 2016, Scudeller et al., 2014, Zaragoza et al.,
2014). Fluconazole and liposomal amphotericin B (L-AMB) were
listed as other initial agents in six (Bow et al., 2010, Elhoufi et al.,
2014, JSMM, 2013, Kohno et al., 2016, Kung et al., 2018,
Montravers et al., 2015) and two (Bassetti et al., 2013, Ruhnke
et al., 2011) CPGs, respectively. Fluconazole was recommended
as an appropriate alternative drug in five CPGs (Alothman et al.,
2014, Bassetti et al., 2013, Colombo et al., 2013, Pappas et al.,
2016, Scudeller et al., 2014), L-AMB in seven (Alothman et al.,
2014, Chen et al., 2014, Colombo et al., 2013, JSMM, 2013, Pappas
et al., 2016, Scudeller et al., 2016, Scudeller et al., 2014),
voriconazole in five (Alothman et al., 2014, Bassetti et al., 2013,
Chen et al., 2014, Luo et al., 2014, Scudeller et al., 2014), and
amphotericin B deoxycholate in four (Alothman et al., 2014,
Chen et al., 2014, JSMM, 2013, Kung et al., 2018).Table 4
Summary of recommendations for targeted treatment for invasive candidiasis (n = 19).
Guideline Title Initial drugs for Candida spp.
mentioned
Alternati
mention
ECH FLU L-AMB D-AMB VOR FLU L-
IDSA guidelines-2016 U U U
MEDICAL: Consensus proposal-2016 U U
2016 IFI Taiwan guidelines-2016 U U U U
French IAI guidelines-2015a U U 
Middle East guidelines-2014 U U U
Australian guidelines-2014 U U U
Iranian IC guidelines-2014 U U 
JMF guidelines-2014 U U U 
EPICO 2.0 project-2014a U 
Chinese burn IFI guidelines-2013 
Italian IAI guidelines-2013a U U U 
ITALIC-2013 U U U
JSMM Guidelines-2013 U U U
ESCMID guidelines-2012 U U U
Brazilian guidelines-2012 U U U
ATS guidelines-2011 U U U U U 
German guidelines-2011 U U U
Spanish guideline for IC-2011 U U
Canadian guidelines-2010 U U
ECH, Echinocandin; FLU, Fluconazole; L-AMB, Liposomal amphotericin B; D-AMB, Amp
a Guidelines for intra-abdominal candidiasis.Five CPGs recommended a duration of two weeks for empirical
therapy for suspected IC in patients who improve (Alothman et al.,
2014, Bow et al., 2010, Elhoufi et al., 2014, Pappas et al., 2016,
Zaragoza et al., 2014). Only two CPGs gave specific details about
when to stop empirical antifungal treatment, i.e., in the absence of
clinical response to empirical antifungal therapy at 4–5 days and if
there is no subsequent evidence of IC after starting empirical
therapy or a negative non-culture-based diagnostic assay with a
high negative predictive value (Bassetti et al., 2013, Pappas et al.,
2016).
Targeted treatment for IC
All 18 candidiasis CPGs and the single burn IFI guideline
included specific recommendations for targeted treatment of IC
(Table 4). All 18 candidiasis CPGs recommended echinocandins as
the initial drug for Candida spp. (Aguado et al., 2011, Alothman
et al., 2014, Bassetti et al., 2013, Bow et al., 2010, Chen et al., 2014,
Colombo et al., 2013, Cornely et al., 2012, Elhoufi et al., 2014, JSMM,
2013, Kohno et al., 2016, Kung et al., 2018, Limper et al., 2011,
Montravers et al., 2015, Pappas et al., 2016, Ruhnke et al., 2011,
Scudeller et al., 2016, Scudeller et al., 2014, Zaragoza et al., 2014)
but the burn IFI guideline did not recommend any specific drugs for
unidentified Candida spp. Fluconazole, L-AMB, amphotericin B
deoxycholate (D-AMB), and voriconazole were mentioned in six
(JSMM, 2013, Kohno et al., 2016, Kung et al., 2018, Limper et al.,
2011, Montravers et al., 2015, Ruhnke et al., 2011), three (Bassetti
et al., 2013, Kohno et al., 2016, Limper et al., 2011), two (Kung et al.,
2018, Limper et al., 2011), and one (Limper et al., 2011) CPGs,
respectively (Table 4). The choice of alternative treatments for
Candida spp. was variable. Notably, itraconazole was only
recommended by two Japanese CPGs (JSMM, 2013, Kohno et al.,
2016). Nine CPGs recommended specific agents for 2 Candida
subspecies (Aguado et al., 2011, Elhoufi et al., 2014, JSMM, 2013,
Kohno et al., 2016, Kung et al., 2018, Limper et al., 2011, Luo et al.,
2014, Montravers et al., 2015, Pappas et al., 2016). None of CPGs
mentioning species-specific therapy recommended fluconazole
and echinocandin as initial therapy for C. glabrata and
C. parapsilosis, respectively (see Table S2).
Most (14 of 15) systematic candidiasis CPGs recommended a
treatment duration of 14 days after documented clearance of
Candida species from the bloodstream and resolution of symptomsve drugs for Candida spp.
ed
Dosage
mentioned
Duration
mentioned
Drugs for 2 Candida
Subspecies mentioned
AMB VOR D-AMB ITR
 U U U U
 U U U
U
 U U U
 U U U
U U U
U U U U U
U
U U
U U
 U U
 U U U U U U
 U U U
 U U
U U U
 U U U
 U U U
 U U U
hotericin B deoxycholate; VOR, Voriconazole; ITR, itraconazole.
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2014, Bow et al., 2010, Chen et al., 2014, Colombo et al., 2013,
Cornely et al., 2012, Elhoufi et al., 2014, JSMM, 2013, Kohno et al.,
2016, Kung et al., 2018, Limper et al., 2011, Pappas et al., 2016,
Ruhnke et al., 2011, Scudeller et al., 2014). Seven CPGs advised that
the end of candidemia should be determined by at least one blood
culture every day or every two days until negativity (Alothman
et al., 2014, Chen et al., 2014, Cornely et al., 2012, Kohno et al., 2016,
Kung et al., 2018, Pappas et al., 2016, Scudeller et al., 2016).
Antifungal treatment for IAC should be continued for at least 10–14
days (Bassetti et al., 2013) or 7–10 days (Zaragoza et al., 2014) after
the beginning of treatment.
All CPGs for systematic candidiasis (n = 15) recommended the
removal of all central lines, if possible (Aguado et al., 2011,
Alothman et al., 2014, Bow et al., 2010, Chen et al., 2014, Colombo
et al., 2013, Cornely et al., 2012, Elhoufi et al., 2014, JSMM, 2013,
Kohno et al., 2016, Kung et al., 2018, Limper et al., 2011, Pappas
et al., 2016, Ruhnke et al., 2011, Scudeller et al., 2016, Scudeller
et al., 2014). The timing of this removal strategy was varied among
CPGs (i.e. as soon as possible (Cornely et al., 2012, Elhoufi et al.,
2014, Kung et al., 2018, Pappas et al., 2016, Ruhnke et al., 2011),
within 48 h (Chen et al., 2014) or 24 h (Kohno et al., 2016) of a
positive blood culture, or waiting 72 h after the initiation of
antifungal therapy (Colombo et al., 2013)). When catheter removal
is not possible, L-AMB or an echinocandin is preferable (mentioned
in three of these CPGs) (Chen et al., 2014, Cornely et al., 2012,
Kohno et al., 2016). The timing of step-down treatment was also
inconsistent among CPGs (i.e. after 10 days treatment (Cornely
et al., 2012, Ruhnke et al., 2011), after 5-7 days treatment (Bassetti
et al., 2013, Kung et al., 2018, Pappas et al., 2016), or undetermined
(Alothman et al., 2014, Bassetti et al., 2013, Bow et al., 2010, Elhoufi
et al., 2014, JSMM, 2013, Kohno et al., 2016, Limper et al., 2011,
Scudeller et al., 2016, Scudeller et al., 2014). Most (13 of 15)
systematic candidiasis CPGs advised that all non-neutropenic
patients with candidemia should have a dilated ophthalmological
examination (Alothman et al., 2014, Chen et al., 2014, Colombo
et al., 2013, Cornely et al., 2012, Elhoufi et al., 2014, JSMM, 2013,
Kohno et al., 2016, Kung et al., 2018, Limper et al., 2011, Pappas
et al., 2016, Ruhnke et al., 2011, Scudeller et al., 2016, Scudeller
et al., 2014).
Discussion
To our knowledge this is the first systematic appraisal of the
methodological quality and content analysis of recommendations
in published CPGs on the use of antifungal agents of IC in non-
neutropenic critically ill patients. In general, the overall quality
score as assessed by the AGREE II tool varied (17% to 100%) and was
generally poor. Only five of 19 CPGs scored 80%. Only the CPG
from ESCMID had scores greater than 70% in all domains except
‘applicability’ (domain 5) (Cornely et al., 2012). The recommen-
dations were consistent in some areas. For example, fluconazole
was commonly recommended as first choice for prophylaxis and
echinocandins for empirical or pre-emptive, and targeted therapy.
However, most guidelines were unclear about some aspects of
treatment, such as when to initiate empirical or pre-emptive
therapy or when to step down.
Most CPGs were transparent about their scope and purpose and
scored well on clarity of presentation (which included having
easily identifiable recommendations). However, they scored very
low on editorial independence, descriptions and use of stakeholder
engagement, and reporting of applicability. These findings are
consistent with other studies that used the AGREE II instrument to
evaluate the CPGs for antifungal treatment for pediatric (Morgan
et al., 2017) and adult hematology/oncology patients (Agrawal
et al., 2012). CPG appraisal studies across a broad range of healthconditions (Erickson et al., 2017, Fuentes Padilla et al., 2016,
Gavriilidis et al., 2017, Lin et al., 2018, Madera Anaya et al., 2018)
showed that poor applicability and lack of editorial independence
is a consistent problem. Applicability is closely linked to
dissemination and implementation of a CPG. The ESCMID guide-
lines had the highest score of this domain (46%). Inadequate
applicability is a barrier to applying CPG recommendations in
practice. To be effective, a CPG needs to be disseminated and
implemented with newer and emerging methods such as smart-
phone apps (Free et al., 2013) or a digital platform for rapid review
(Siemieniuk et al., 2016). In terms of ‘editorial independence’,
although financing bodies and conflicts of interest are often
declared, the methods employed to avoid conflicts of interest are
rarely described within CPG content, leading to low scores.
The issue of using prophylactic antifungals remains controver-
sial. Should this treatment strategy be used to prevent IC in the ICU
setting? No consensus was obvious in the CPGs. In fact, only one in
three CPGs mentioned prophylaxis in non-neutropenic critically ill
patients. Fluconazole prophylaxis was associated with a reduction
in IC in ICU patients in three meta-analyses (Cruciani et al., 2005,
Playford et al., 2006, Shorr et al., 2005); but only one demonstrated
a reduction in mortality from IC (Cruciani et al., 2005). Only two
clinical trials examined echinocandins as a prophylactic treatment
in ICU patients; neither mortality nor the incidence of IC was
improved when micafungin or caspofungin were administered in
this population (Knitsch et al., 2015, Ostrosky-Zeichner et al.,
2014). There are no clear recommendations on the duration of
prophylaxis in non-neutropenic critically ill patients unlike
guidelines for hematology or oncology patients (Morgan et al.,
2017).
In terms of empirical or pre-emptive treatment, the recom-
mended timing of initiation was slightly different among CPGs:
most supported empirical or pre-emptive treatment in critically ill
patients with risk factors for IC or IAC. Several studies have
developed prediction models to identify patients at highest risk.
They are characterized by high specificity, but low sensitivity, thus
missing many patients with IC (Cortegiani et al., 2016b, Leon et al.,
2006, Ostrosky-Zeichner et al., 2011). Few clinical studies have
evaluated the efficacy of empirical or pre-emptive strategies; with
only one randomized clinical trial applying preemptive treatment
and five trials using empirical treatment, in our recent systematic
review (Wang et al., 2017). Although echinocandin was recom-
mended as the initial drug in all 16 CPGs supporting empirical or
pre-emptive treatment, two systematic reviews (Cortegiani et al.,
2016a, Wang et al., 2017) demonstrated that echinocandins and
empirical or pre-emptive treatment did not significantly impact on
preventing proven IFIs. There are no data guiding the appropriate
duration of empirical or pre-emptive antifungal therapy, but it is
reasonable to think that it should not differ from the treatment of
documented IC.
For the management of proven IC or IAC, most CPGs
recommended treatment with both echinocandins and flucona-
zole, although these CPGs suggest that echinocandins are
increasingly considered as first-line therapy over fluconazole
(Cornely et al., 2012, Pappas et al., 2016). The CPGs noted important
roles for L-AMB and voriconazole as alternative treatment options.
Referring to species-specific therapy, C. glabrata and C. parapsilosis
are the two most problematic infections in determining treatment
choice. None of the CPGs mentioning species-specific therapy
recommended fluconazole or echinocandin as initial therapy for
C. glabrata and C. parapsilosis, respectively. There is no evidence
that the clinical outcome of therapy with fluconazole is inferior to
echinocandins in patients with C. glabrata, even though C. glabrata
is less susceptible to fluconazole in vitro (Eschenauer et al., 2013,
Reboli et al., 2007). Meanwhile, there was no difference in the risk
of clinical failure among 200 patients with candidemia due to
144 Y. Wang et al. / International Journal of Infectious Diseases 89 (2019) 137–145C. parapsilosis who received initial treatment with an echinocandin
compared with those who received other regimens (Fernandez-
Ruiz et al., 2014), in spite of the laboratory observations of
decreased in vitro activity of echinocandin (Pfaller et al., 2011).
Additionally, we noted that the timing of step-down therapy was
different among CPGs (e.g. 10 days in ESCMID (Cornely et al., 2012)
versus 5-7 days in IDSA (Pappas et al., 2016)). CPGs fail to provide
adequate information on this issue due to a lack of high-level
evidence (Vazquez et al., 2014).
The main strength of our systematic review lies in the
integration of methodological quality appraisal with content
analysis of recommendations; no other study has provided an
inter-dimensional approach to CPG quality assessment. The matrix
method used will also enable CPG developers and users to clearly
identify gaps in treatment recommendations that can be rectified
in subsequent updates.
Our search was not restricted to only English: our multilingual
team assessed guidelines in Chinese, Japanese, and Spanish. This
enabled a global CGP assessment and reduced the risk of
recommendation bias towards CPGs in English. However, we still
may have missed relevant non-English language CPGs in journals
not indexed by major bibliographic databases.
A study limitation is that the AGREE II scores may reflect the
quality of reporting rather than methodological quality. Subopti-
mal reporting of the development process could potentially
undermine the credibility of the CPGs. Nevertheless, the AGREE
II is a benchmark for assessing CPG quality that has been
extensively validated (Lin et al., 2018). Even though AGREE II only
evaluates methodological processes and not necessarily recom-
mendations, we are then able to pay more attention to the
recommendations provided by CPGs that scored higher on AGREE
II criteria. The AGREE II scores of CPGs were appraised by two
reviewers, with three reviewers involved in the quality assurance
review; however, ideally four reviewers should be used (Brouwers
et al., 2010b).
Conclusions
In summary, the methodological quality of CPGs for the use of
antifungal agents in non-neutropenic critically ill patients is
suboptimal. These findings highlight the need for better reporting
of guideline development processes in the future. Further
improvement in the ‘applicability’ domains of the AGREE II
criteria would strengthen the quality of the CPGs. Although these
CPGs have access to the same published evidence base,
recommendations remain unclear or inconsistent in certain
areas. The similarities across CPGs add validity and credibility
to the recommendations. The differences point to areas that need
further research to strengthen the evidence base; however, they
will need careful consideration and adaptation to the local health
services context in order to address the key clinical issues that
clinicians face.
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